摘要
目的探讨检测血浆可溶性OX40配体对冠状动脉介入治疗后患者主要不良心血管事件的预测价值。方法连续入选2014年3月至2015年3月于锦州市中心医院成功施行冠状动脉介入治疗并自愿随访的患者116例,检测两组患者血浆可溶性OX40配体、血生化及超声心动图等指标。术后随访1年,根据是否发生主要不良心血管事件分为不良事件组及无不良事件组,比较两组患者的一般临床指标、超声心动图、血生化、可溶性OX40配体等指标,并运用受试者工作特征曲线评价可溶性OX40配体对主要不良心血管事件的预测价值。结果不良事件组患者血浆可溶性OX40配体水平显著高于无不良事件组[(27.82±6.47)ng/m L vs.(20.96±5.62)ng/m L,P=0.000],差异有统计学意义;Logistic多因素回归分析显示,可溶性OX40配体升高是冠状动脉介入治疗后主要不良心血管事件发生的独立危险因素(优势比=5.056,P=0.003);在可溶性OX40配体预测主要不良心血管事件能力的受试者工作曲线中,其曲线下面积为0.782(P<0.001);当血浆可溶性OX40配体取25.79 ng/m L时,其阳性预测值为71.4%,阴性预测值为96.8%。结论冠心病患者血浆可溶性OX40配体升高对冠状动脉介入治疗后主要不良心血管事件的发生具有一定的预测价值,血浆可溶性OX40配体水平超过25.79ng/m L时患者术后发生主要不良心血管事件的风险较大。
Objective To explore the predictive value of plasma soluble OX40 ligand（s OX40L）levels on the major adverse cardiovascular events（MACE）in patients after percutaneous coronary intervention（PCI）. Methods A total of 116 patients with acute coronary syndrome or stable angina pectoris successfully treated with PCI were selected between March 2014 and March 2015. All the patients were followed up for one year after treatement. Study subjects were divided into MACE group and non-MACE group. The plasma s OX40 L and other clinical biochemical patameters were detected and their predictive value on MACE was assessed. Results The level of plasma s OX40 L was significantly higher in MACE group than that in non-MACE group in statistics（P=0.000）. Multivariate logistic regression analysis revealed that the higher plasma s OX40 L level was an independent risk factor of MACE（OR=5.056,P=0.003）. Area under the curve for s OX40 L in evaluating prognosis of MACE was 0.782（P0.001）. The optimal cut off value of s OX40 L was 25.79 ng/m L,at the point,the positive predictive value and negative predictive value were 71.4% and96.8%. Conclusions There are certain predictive value of plasma sOX40 L level for the occurrence MACE after PCI.When the level of sOX40 L is higher than 25.79 ng/mL,the risk of MACE is greater.
出处
《循证医学》
CSCD
2017年第1期55-58,共4页
The Journal of Evidence-Based Medicine
